KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non Operating Income: 2011-2025

Historic Other Non Operating Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to $2.3 million.

  • Supernus Pharmaceuticals' Other Non Operating Income fell 44.44% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.2 million, marking a year-over-year increase of 22.66%. This contributed to the annual value of $16.2 million for FY2024, which is 55.02% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Other Non Operating Income stood at $2.3 million, which was down 49.71% from $4.5 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' Other Non Operating Income's 5-year high stood at $14.7 million during Q1 2022, with a 5-year trough of -$21.5 million in Q4 2021.
  • Moreover, its 3-year median value for Other Non Operating Income was $3.7 million (2024), whereas its average is $3.4 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Other Non Operating Income slumped by 871.62% in 2021, and later skyrocketed by 285.57% in 2022.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Other Non Operating Income stood at -$21.5 million in 2021, then spiked by 111.14% to $2.4 million in 2022, then decreased by 17.25% to $2.0 million in 2023, then soared by 150.60% to $5.0 million in 2024, then crashed by 44.44% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q3 2025, $4.5 million for Q2 2025, and $4.4 million during Q1 2025.